SHAREHOLDER ALERT: Berger Montague Reminds Ultragenyx Pharmaceutical Inc. (RARE) Investors of a Class Action Lawsuit Deadline

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. on behalf of investors who purchased shares during the specified Class Period, alleging misrepresentation of clinical trial results [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx misrepresented the results of the ORBIT and COSMIC Phase 3 programs for setrusumab, a treatment for Osteogenesis Imperfecta [3]. - Investors were informed on December 29, 2025, that neither clinical trial met its primary endpoint, leading to a significant drop in the company's share value by over 42% in one trading day [3]. Group 2: Company Overview - Ultragenyx is a biopharmaceutical company based in Novato, California, focused on developing novel products for rare diseases [2]. - The company is involved in the acquisition and development of treatments aimed at addressing unmet medical needs in rare disease populations [2].